(PBH, THLD, CRWE) PennyOmega.com Stocks In Action

PBH, Prestige Brand Holdings, Inc.

** Genomma Lab Internacional, S.A.B. de C.V. reported that it has submitted a non-binding proposal to acquire all of the outstanding shares of PBH common stock for $16.60 dollars per share in cash. The transaction is valued at approximately $834 million dollars, not including PBH’s net debt.

PBH markets and distributes brand name over-the-counter and household cleaning products throughout the U.S., Canada, and certain international markets.

More about PBH at www.prestigebrandsinc.com

***************

THLD, Threshold Pharmaceuticals, Inc.

** THLD reported that its 214 patient randomized controlled Phase 2b clinical trial evaluating the efficacy and safety of two doses of the investigational agent TH-302 in combination with gemcitabine compared to gemcitabine alone in patients with first-line advanced pancreatic cancer achieved its primary endpoint, with a 63% improvement in progression free survival and a safety profile consistent with previous studies.

TH-302 is a hypoxia-targeted drug that is thought to be activated under tumor hypoxic conditions, a hallmark of many cancer indications.

THLD is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of some hematologic malignancies.

More about THLD at www.thresholdpharm.com

***************

Crown Equity Holdings Inc., CRWE.OB

** CRWE reported that its subsidiary Crown Tele Services Inc. (www.crownteleservices.com) has entered into 2 letters of intent, one with BBN Solutions (located in India) and the other with MVOX AG (located in Germany). CRWE also reported that it has launched two new online service companies: CRWE Real Estate (www.crwerealestate.com) and and CRWE Direct (www.crwedirect.com).

CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. CRWE’s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.

More about CRWE at www.crownequityholdings.com.

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Tags: crown equity holdings, CRWE, Genomma Lab, NASDAQ:THLD, NYSE:PBH, OTC:CRWE, Prestige Brands, THLD, Threshold Pharmaceuticals